Startup Diligence
Diligence report Healthcare & Life Sciences; digital health; patient access; practice management Late-stage private unicorn

Doctolib

Doctolib Public-Source Startup Diligence Report

Track and verify rather than underwrite from public data alone. The upside case depends on converting healthcare workflow reach into multi-product ARR and operating leverage while maintaining health-data trust and regulatory compliance.

Company profile

Doctolib Public-Source Startup Diligence Report

Doctolib is a credible late-stage European digital-health unicorn with rare patient/provider distribution, but public diligence surfaces material risk around profitability, liquidity, legal scrutiny, security/privacy, AI governance, and monetization quality.

Website
www.doctolib.fr
Sector
Healthcare & Life Sciences; digital health; patient access; practice management
Geography
France headquarters with operations in France, Germany, Italy and the Netherlands
Stage
Late-stage private unicorn
Known aliases
Doctolib SAS, DOCTOLIB, Doctolib GmbH, Siilo
Report version
1.0
Timezone
UTC

Executive summary

Strengths

  • Doctolib is a credible late-stage European digital-health unicorn with rare patient/provider distribution, but public diligence surfaces material risk around profitability, liquidity, legal scrutiny, security/privacy, AI governance, and monetization quality.

Risks

    Gaps

    • ARR, gross margin, NRR, churn, CAC, payback, contract terms, customer concentration, and country P&Ls.
    • Cap table, preference stack, debt maturity, covenants, cash runway, and post-2024 financing status.
    • Customer references, practitioner-count definitions, support data, security audit scopes, incident logs, DPAs, and AI governance artifacts.

    Recommended next steps

    • Request audited consolidated financials, monthly management accounts, current cash, and debt documents.
    • Validate financing terms and valuation against cap table, debt agreements, and preference stack.
    • Conduct clinician/customer calls in France, Germany, and Italy.
    • Review security certifications, incident history, DPAs, and AI governance controls.
    • Model downside runway and legal/security shock scenarios before any valuation work.

    Risk register

    high medium likelihood

    R-001:

    Public 2024 filings show meaningful EBITDA and net losses with cash materially below reported financial debt.

    high medium likelihood

    R-002:

    Public French competition authority penalty and appeal posture create legal, reputational, and conduct-remedy uncertainty.

    high medium likelihood

    R-004:

    Public scale does not disclose paying seats, ARR quality, churn, NRR, or customer concentration.

    high low likelihood

    R-003:

    Large health-data workflow platform creates high impact if availability, confidentiality, or integrity fails.

    medium medium likelihood

    R-005:

    AI-enabled healthcare workflow tools require strong governance, validation, monitoring, and user controls.

    medium medium likelihood

    R-006:

    Operations across several countries and healthcare systems increase localization, support, and compliance burden.

    medium medium likelihood

    R-007:

    Regional appointment platforms, EHR vendors, and public-sector initiatives can pressure supply acquisition and pricing.

    medium low likelihood

    R-009:

    Public references to cloud and processors imply dependency and contract risk for critical health-data workflows.

    Chapter 01

    01Unicorn eligibility, identity, and framing

    No public summary available.

    I.A Company snapshot and diligence objective

    — confidence: high

    No public summary available.

    EC-003EC-004
    Corporate identity snapshot
    ———
    ———
    ———
    ———
    ———
    Company timeline Key public milestones.

    I.B Private-unicorn status and valuation

    — confidence: high

    No public summary available.

    EC-001EC-002EC-011
    Valuation and financing anchors
    ————
    ————
    ————
    ————
    Valuation anchors Public valuation reference points.

    I.C Public claim verification map

    — confidence: medium

    No public summary available.

    EC-001EC-004EC-009EC-018
    Claim verification map
    ————
    ————
    ————
    ————
    ————
    Claim confidence funnel Public claims converted into diligence-ready evidence.

    I.D Diligence posture and gating questions

    — confidence: medium

    No public summary available.

    EC-007EC-013EC-014
    Gating diligence questions
    ————
    ————
    ————
    ————
    ————
    Risk heatmap Highest-priority diligence risks.
    Chapter 02

    02Product, technology, and defensibility

    No public summary available.

    II.A Product suite, workflow coverage, and architecture

    — confidence: medium

    No public summary available.

    EC-006EC-009EC-010EC-014
    Product and security surface
    ———
    ———
    ———
    ———
    ———
    ———
    Product diligence gap matrix
    ———
    ———
    ———
    ———
    ———
    Product and data architecture view Simplified public-source workflow architecture.
    Chapter 03

    03Market, customers, and competition

    No public summary available.

    III.A Customer segments and adoption evidence

    — confidence: medium

    No public summary available.

    EC-004EC-005
    Public adoption indicators
    ————
    ————
    ————
    ————
    ————
    Public scale indicators Selected company-published scale metrics.

    III.B Market size and growth vectors

    — confidence: medium

    No public summary available.

    EC-004EC-006EC-016
    Market growth vectors
    ———
    ———
    ———
    ———
    ———
    Market map Doctolib and adjacent competitive categories.

    III.C Competitive landscape and positioning

    — confidence: medium

    No public summary available.

    EC-012EC-013EC-016
    Competitive landscape summary
    ———
    ———
    ———
    ———
    ———

    III.D Go-to-market, pricing, and channel economics

    — confidence: low

    No public summary available.

    EC-002EC-004EC-017
    Go-to-market and pricing evidence
    ———
    ———
    ———
    ———
    ———

    III.E Customer concentration and satisfaction proxies

    — confidence: low

    No public summary available.

    EC-004EC-005EC-015
    Customer quality evidence gaps
    ———
    ———
    ———
    ———
    ———
    Customer diligence funnel Public scale must convert into verified customer economics.
    Chapter 04

    04Team, governance, and organization

    No public summary available.

    IV.A Founders, leadership, board, and talent base

    — confidence: medium

    No public summary available.

    EC-004EC-008EC-012
    Leadership and organization snapshot
    ———
    ———
    ———
    ———
    ———
    Governance and people diligence requests
    ———
    ———
    ———
    ———
    ———
    Public leadership organization chart Publicly identified organization nodes.
    Chapter 05

    05Business model, unit economics, and financial performance

    No public summary available.

    V.A Revenue model and monetization

    — confidence: low

    No public summary available.

    EC-002EC-006EC-007EC-017
    Revenue model hypotheses
    ———
    ———
    ———
    ———
    ———
    Revenue growth with profitability caveat Public revenue trajectory and 2024 losses.

    V.B Historical financial performance

    — confidence: high

    No public summary available.

    EC-007
    Public financial summary
    —————
    —————
    —————
    —————
    —————

    V.C Cash runway, debt, and financing capacity

    — confidence: medium

    No public summary available.

    EC-002EC-007
    Balance sheet and financing risk anchors
    ———
    ———
    ———
    ———
    ———

    V.D Unit economics and operating leverage

    — confidence: low

    No public summary available.

    EC-007EC-017
    Unit-economics diligence matrix
    ———
    ———
    ———
    ———
    ———
    ———

    V.E Forecast scenarios and value drivers

    — confidence: medium

    No public summary available.

    EC-001EC-004EC-007EC-013
    Scenario frame
    ———
    ———
    ———
    ———
    Diligence decision tree Branches for moving from public diligence to underwriting.
    other

    No renderer is wired up for this figure type yet. Source data remains in the report YAML.

    Chapter 06

    06Legal, IP, and regulatory

    No public summary available.

    VI.A Corporate status, ownership, and IP/public records

    — confidence: high

    No public summary available.

    EC-003
    Corporate and ownership records checklist
    ———
    ———
    ———
    ———
    ———

    VI.B Regulatory, litigation, and compliance posture

    — confidence: medium

    No public summary available.

    EC-009EC-010EC-013EC-014
    Legal and regulatory matter tracker
    ———
    ———
    ———
    ———
    ———
    Chapter 07

    07Operations, security, and execution risk

    No public summary available.

    VII.A Operating footprint, delivery model, and process maturity

    — confidence: medium

    No public summary available.

    EC-004EC-008
    Operating footprint and execution controls
    ———
    ———
    ———
    ———
    ———
    Operations, security, and dependency control map Operating dependencies and controls that must be validated for a multi-country health-data platform.

    VII.B Security, privacy, and data governance

    — confidence: medium

    No public summary available.

    EC-009EC-010
    Security and dependency audit checklist
    ———
    ———
    ———
    ———
    ———

    VII.C Reliability, availability, and business continuity

    — confidence: low

    No public summary available.

    EC-005EC-006EC-010

    VII.D Third-party dependencies and supply chain

    — confidence: low

    No public summary available.

    EC-010

    VII.E AI, automation, and clinical-safety governance

    — confidence: low

    No public summary available.

    EC-014
    Confirmatory diligence workplan by workstream
    ———
    ———
    ———
    ———
    ———

    VII.F People, culture, and hiring execution

    — confidence: low

    No public summary available.

    EC-008EC-012

    VII.G Fraud, abuse, and platform integrity

    — confidence: low

    No public summary available.

    EC-006EC-015
    Chapter 08

    08Investment decision, diligence plan, and monitoring

    No public summary available.

    VIII.A Integrated diligence conclusion

    — confidence: medium

    No public summary available.

    EC-001EC-004EC-007EC-013
    Red-flag and repricing thresholds
    ———
    ———
    ———
    ———
    ———

    VIII.B Confirmatory diligence workplan

    — confidence: high

    No public summary available.

    EC-002EC-007EC-009EC-013

    VIII.C Red flags and stop criteria

    — confidence: medium

    No public summary available.

    EC-001EC-007EC-013

    VIII.D Valuation framing and sensitivity

    — confidence: medium

    No public summary available.

    EC-001EC-002EC-007

    VIII.E Monitoring plan and KPIs

    — confidence: medium

    No public summary available.

    EC-007EC-013EC-014
    Monitoring KPI plan
    ———
    ———
    ———
    ———
    ———

    VIII.F Data-room request list

    — confidence: high

    No public summary available.

    EC-007EC-009EC-013

    VIII.G Final recommendation

    — confidence: medium

    No public summary available.

    EC-001EC-004EC-007EC-013

    Evidence

    Evidence claims
    IDClaimStatusSources
    EC-001 CB Insights lists Doctolib as a France-based Healthcare & Life Sciences unicorn valued at $6.40B with unicorn entry date 2019-03-19. verified high SRC-001
    EC-002 Tech.eu reported Doctolib raised EUR 500M in equity/debt in 2022 at a EUR 5.8B valuation and cited a EUR 129/month SaaS reference. verified high SRC-002
    EC-003 Pappers identifies Doctolib as an active French SAS with SIREN 794 598 813 and share capital of EUR 201,304.25. verified high SRC-003
    EC-004 Doctolib public pages describe about 90M patients, 500k to 520k healthcare professionals, roughly 3,000 employees, and more than 30 cities. partially verified medium SRC-005SRC-006
    EC-005 Doctolib public pages cite about 22M appointments per month, about 15M online appointments per month, 35M video consultations, and 14M documents per month. partially verified medium SRC-005SRC-006
    EC-006 Public product pages show scheduling, telehealth, patient messaging, document sharing, payments, practice-management, and related workflow modules. verified medium SRC-005
    EC-007 Pappers public financials show revenue of EUR 164M, EUR 189M, EUR 216M, and EUR 253M for 2021-2024, plus 2024 EBITDA about negative EUR 62.9M, net income about negative EUR 122M, cash about EUR 28.6M, and financial debt about EUR 104M. verified high SRC-003
    EC-008 Doctolib careers/about materials indicate a large organization of roughly 3,000 employees across more than 30 cities. partially verified medium SRC-006
    EC-009 Doctolib security/privacy pages cite HDS hosting, ISO 27001, ISO 27701, C5 Germany, ACN Italy, EU hosting, and encryption controls. partially verified medium SRC-008SRC-009
    EC-010 Doctolib public supplier/privacy references identify cloud or processor dependencies including AWS, Devoteam G Cloud, and Cloudinary. partially verified medium SRC-010
    EC-011 Secondary public sources corroborate a 2013 founding date and valuation in the $6B range. partially verified medium SRC-011SRC-016
    EC-012 Public people sources identify Stanislas Niox-Chateau as co-founder/CEO and list a broader executive roster with limited board detail. partially verified medium SRC-012
    EC-013 French competition authority materials report a EUR 4.665M penalty and Doctolib's public disagreement/appeal posture. verified high SRC-013
    EC-014 Doctolib public product materials reference AI-enabled or automated workflow tools, but detailed AI governance evidence is not public. partially verified low SRC-014
    EC-015 Public sources do not disclose customer concentration, retention cohorts, active paid practitioners, NRR, or NPS. not publicly verifiable high SRC-005
    EC-016 The competitive set includes appointment platforms, practice-management/EHR vendors, telehealth tools, public portals, and adjacent healthcare software. partially verified medium SRC-013SRC-014SRC-015
    EC-017 Public evidence does not disclose ARR, gross margin, CAC payback, NRR, churn, contract terms, country profitability, or module-level economics. not publicly verifiable high SRC-002SRC-003SRC-005
    EC-018 Public evidence supports strategic relevance but is insufficient to prove a durable, profitable healthcare operating-system thesis. inconclusive medium SRC-001SRC-003SRC-005SRC-013
    Sources
    IDPublisherTitleAccessed
    SRC-001 CB Insights CB Insights - The Complete List Of Unicorn Companies 2026-05-16
    SRC-002 Tech.eu Tech.eu - Doctolib raises EUR 500M at EUR 5.8B valuation 2026-05-16
    SRC-003 Pappers Pappers - Doctolib company profile and financials 2026-05-16
    SRC-004 Doctolib Doctolib official website 2026-05-16
    SRC-005 Doctolib Doctolib about and product pages 2026-05-16
    SRC-006 Doctolib Doctolib careers and company pages 2026-05-16
    SRC-007 Doctolib Doctolib press and newsroom pages 2026-05-16
    SRC-008 Doctolib Doctolib security page 2026-05-16
    SRC-009 Doctolib Doctolib privacy and data-protection materials 2026-05-16
    SRC-010 Doctolib Doctolib supplier and processor references 2026-05-16
    SRC-011 CB Insights CB Insights company profile - Doctolib 2026-05-16
    SRC-012 CB Insights CB Insights people profile - Doctolib 2026-05-16
    SRC-013 French Competition Authority Autorite de la concurrence - Doctolib competition matter 2026-05-16
    SRC-014 Doctolib Doctolib AI and product communications 2026-05-16
    SRC-015 Analyst synthesis from cited public sources Public healthcare software market observations 2026-05-16
    SRC-016 Wikipedia Wikipedia - List of unicorn startup companies 2026-05-16

    Disclaimer

    This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.